AllianceBernstein
VTGN icon

AllianceBernstein’s VistaGen Therapeutics VTGN Stock Holding History

AllianceBernstein’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-10,530
Closed -$39.4K – 3252
2023
Q1 		$39.4K Hold
10,530
– – ﹤0.01% 3106
2022
Q4 		$32.5K Buy
10,530
+4,573
+77% +$17.2K ﹤0.01% 3197
2022
Q3 		$27K Buy
5,957
+4,854
+440% +$48.1K ﹤0.01% 3204
2022
Q2 		$29K Buy
1,103
+383
+53% +$13.5K ﹤0.01% 3191
2022
Q1 		$27K Sell
720
-600
-45% -$26.2K ﹤0.01% 3208
2021
Q4 		$77K Hold
1,320
– – ﹤0.01% 3217
2021
Q3 		$109K Hold
1,320
– – ﹤0.01% 3176
2021
Q2 		$125K Buy
+1,320
New +$97.8K ﹤0.01% 3220

Other funds holding VTGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
CSS
Cubist Systematic Strategies Stamford, Connecticut $21B AUM 21.48% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein's VTGN Position: Q2 2023 in Review

AllianceBernstein sold out of VistaGen Therapeutics (VTGN) in Q2 2023, closing a stake of 10,530 shares — an estimated $39.4K sold.

AllianceBernstein first reported a position in VTGN in Q2 2021 and held it in 8 quarters. The position peaked at $125K in Q2 2021. 33 funds tracked by Wall St. Rank hold VTGN as of Q2 2023.

  • AllianceBernstein reported no remaining VistaGen Therapeutics position as of Q2 2023 after selling out during the quarter.
  • AllianceBernstein sold 10,530 VistaGen Therapeutics shares in Q2 2023, an estimated $39.4K.
  • AllianceBernstein first reported a position in VistaGen Therapeutics in Q2 2021 and held it in 8 quarters.
  • AllianceBernstein's VistaGen Therapeutics position peaked at $125K in Q2 2021.
  • 33 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2023.

Based on AllianceBernstein's 13F filing for Q2 2023, filed 15 Aug 2023.